Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In Vitro
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Hepatocellular carcinoma (HCC) is a leading cause for deaths worldwide. Histone deacetylase (HDAC) inhibition (HDACi) is emerging as a promising therapeutic strategy. However, most pharmacological HDACi unselectively block different HDAC classes and their molecular mechanisms of action are only incompletely understood. The aim of this study was to systematically analyze expressions of different HDAC classes in HCC cells and tissues and to functionally analyze the effect of the HDACi suberanilohydroxamic acid (SAHA) and trichostatin A (TSA) on the tumorigenicity of HCC cells. The gene expression of all HDAC classes was significantly increased in human HCC cell lines (Hep3B, HepG2, PLC, HuH7) compared to primary human hepatocytes (PHH). The analysis of HCC patient data showed the increased expression of several HDACs in HCC tissues compared to non-tumorous liver. However, there was no unified picture of regulation in three different HCC patient datasets and we observed a strong variation in the gene expression of different HDACs in tumorous as well as non-tumorous liver. Still, there was a strong correlation in the expression of HDAC class IIa (HDAC4, 5, 7, 9) as well as HDAC2 and 8 (class I) and HDAC10 (class IIb) and HDAC11 (class IV) in HCC tissues of individual patients. This might indicate a common mechanism of the regulation of these HDACs in HCC. The Cancer Genome Atlas (TCGA) dataset analysis revealed that HDAC4, HDAC7 and HDAC9 as well as HDAC class I members HDAC1 and HDAC2 is significantly correlated with patient survival. Furthermore, we observed that SAHA and TSA reduced the proliferation, clonogenicity and migratory potential of HCC cells. SAHA but not TSA induced features of senescence in HCC cells. Additionally, HDACi enhanced the efficacy of sorafenib in killing sorafenib-susceptible cells. Moreover, HDACi reestablished sorafenib sensitivity in resistant HCC cells. In summary, HDACs are significantly but differently increased in HCC, which may be exploited to develop more targeted therapeutic approaches. HDACi affect different facets of the tumorigenicity of HCC cells and appears to be a promising therapeutic approach alone or in combination with sorafenib.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Histone Deacetylase Inhibitors as Anticancer Drugs
Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071414 · Cited by 1,206 · cited 1×
“Among these, histone deacetylases (HDACs) have been shown to play a key role in different hallmarks of cancer including resistance to apoptosis and chemotherapy resistance [4,5].”
BackgroundSchroeder, F. A., Lewis, M. C., Fass, D. M., Wagner, F. F., Zhang, Y.-L., Hennig, K. M., Gale, J., Zhao, W.-N., Reis, S., Barker, D. D., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071323 · Cited by 146 · cited 2×
“SAHA effectively inhibits class I and II HDACs with higher IC50 for HDAC 4, 7 and 9 [13].”
Background
Cited by
Epigenetics in hepatocellular carcinoma
Nagaraju, G. P., Dariya, B., Kasa, P., Peela, S., & El-Rayes, B. F. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.07.017 · Cited by 339
Baselious, F., Hilscher, S., Robaa, D., Barinka, C., Schutkowski, M., & Sippl, W. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021358 · Cited by 32
Rusu, I., Pirlog, R., Chiroi, P., Nutu, A., Puia, V. R., Fetti, A. C., Rusu, D. R., Berindan-Neagoe, I., & Al Hajjar, N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012370 · Cited by 27
HDAC2 and 7 down-regulation induces senescence in dermal fibroblasts
Warnon, C., Bouhjar, K., Ninane, N., Verhoyen, M., Fattaccioli, A., Fransolet, M., Lambert de Rouvroit, C., Poumay, Y., Piel, G., Mottet, D., et al. (2021) · Aging · doi:10.18632/aging.203304 · Cited by 25
Baselious, F., Robaa, D., & Sippl, W. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.107700 · Cited by 20
Metadata
- Authors
- Freese, K., Seitz, T., Dietrich, P., Lee, S. M. L., Thasler, W. E., Bosserhoff, A., & Hellerbrand, C.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2019-10-18
- Volume
- 11
- Issue
- 10
- Pages
- 1587
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W2981033204
- Cited by
- 123
- References
- 2
- FWCI
- 4.44
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In Vitro. https://app.cochat.ai/papers/10.3390/cancers11101587
- The paper
- Freese, K., Seitz, T., Dietrich, P., Lee, S. M. L., Thasler, W. E., Bosserhoff, A., & Hellerbrand, C. (2019). Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In Vitro. Cancers. https://doi.org/10.3390/cancers11101587
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.